Opinion statement
The use of adjuvant chemotherapy in soft tissue sarcomas (STS) continues to be an area of controversy; however, the group of investigators favoring the use of an anthracycline- and ifosfamide-based regimen for high-risk (American Joint Committee on Cancer stage III) extremity STS is steadily increasing. The historic 5-year survival rate of approximately 50% in this high-risk group treated with local therapy alone represents a poor standard of care, thus there is a need to incorporate systemic therapy early in the management of these patients. Published data from the meta-analysis of doxorubicin-based adjuvant chemotherapy trials and the prospective randomized data with epirubicin and ifosfamide from the Italian Sarcoma Group are frequently used as rationale for this approach. In a rare and heterogenous group of diseases, such as STS, physicians run into negative studies for various reasons that have little to do with the efficacy of the treatment being tested. The wisdom may be in capitalizing further on a positive lead as opposed to nihilism. It is appropriate to acknowledge that the chemotherapeutic agents have limited efficacy and are toxic, especially when used at full therapeutic doses. Selecting patients in whom there is some evidence of benefit, justifying the poor quality of life from receiving chemotherapy, becomes very important. This rationale, with the lessons learned from osteosarcoma research, forms the basis for neoadjuvant chemotherapy for STS. Until we reach the day when we have identified critical tumorigenic targets and their effective inhibitors for most of these tumors, we are obligated to use the available therapeutic armamentarium in the best possible sequence.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5–26.
Le Doussal V, Coindre JM, Leroux A, et al.: Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 1996, 77:1823–1830.
Le QT, Fu KK, Kroll S, et al.: Prognostic factors in adult soft tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys 1997, 37:975–84.
Vraa S, Keller J, Nielsen OS, et al.: Prognostic factors in soft tissue sarcomas: the Aarhus experience. Eur J Cancer 1998, 34:1876–1882.
Coindre JM, Terrier P, Guillou L, et al.: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001, 91:1914–1926.
Collin CF, Friedrich C, Godbold J, et al.: Prognostic factors for local recurrence and survival in patients with localized extremity soft tissue sarcoma. Semin Surg Oncol 1988, 4:30–27.
Watson DI, Coventry BJ, Langlois SL, et al.: Soft tissue sarcoma of the extremity: experience with limb-sparing surgery. Med J Aust 1994, 160:412–416.
Pisters PW, Leung DH, Woodruff J, et al.: Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679–1689.
Delaney TF, Yang JC, Glatstein E: Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology (Huntingt) 1991, 5:105–118.
Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
Frustaci S, Gherlinzoni F, De Paoli A, et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001, 19:1238–1247. A prospective randomized trial of appropriate chemotherapy in appropriately selected high-risk patients showing proof-of-principle benefit in recurrence-free interval, relapse-free survival, and overall survival.
Skibber JM, Lotze MT, Seipp CA, et al.: Limb-sparing surgery for soft tissue sarcomas: wound-related morbidity in patients undergoing wide local excision. Surgery 1987, 102:447–452.
Meric F, Milas M, Hunt KK, et al.: Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 2000, 18:3378–3383. A retrospective review of a single-institution experience with dose-intensive neoadjuvant chemotherapy (and radiotherapy) showing an impact on survival without adversely affecting surgical outcome.
Edmonson JH, Petersen IA, Shives TC, et al.: Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage colony- stimulating factor. Cancer 2002, 94:786–792. Promising survival data in a single-arm trial of neoadjuvant chemotherapy followed by local therapy.
Kraybill WG, Harris JH, Spiro IJ, et al.: Radiation Therapy Oncology Group (RTOG) 9514: a phase II study of neo-adjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high-risk (HR), high-grade, soft tissue sarcomas (STS) of the extremities and body wall [abstract]. Proc Am Soc Clin Oncol 2003, 3276.
Eilber FC, Rosen G, Eckardt J, et al.: Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001, 19:3203–3209. Interesting data in a large cohort of patients supporting the value of pathologic necrosis as a predictor of survival.
Eilber F, Eckardt J, Rosen G, et al.: Preoperative therapy for soft tissue sarcomas. Hematol Oncol Clin North Am 1995, 9:817–823.
Jones JJ, Catton CN, O'Sullivan B, et al.: Initial results of a trial of preoperative external beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol 2002, 9:346–354.
Robertson JM, Sondak VK, Weiss SA, et al.: Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 1995, 31:87–92.
Azzarelli A, Quagliuolo V, Casali P, et al.: Preoperative doxorubicin plus ifosfamide in primary soft tissue sarcomas of the extremities. Cancer Chemother Pharmacol 1993, 31:S210-S212.
Casper ES, Gaynor JJ, Harrison LB, et al.: Preoperative and postoperative adjuvant combination chemotherapy for adults with high-grade soft tissue sarcoma. Cancer 1994, 73:1644–1651.
Pisters PW, Patel SR, Varma DG, et al.: Preoperative chemotherapy for stage IIIB extremity soft tissue sarco-mas: long-term results from a single institution. J Clin Oncol 1997, 15:3481–3487.
Gortzak E, Azzarelli A, Buesa J, et al.: A randomised phase II study on neoadjuvant chemotherapy for high-risk adult soft tissue sarcoma. Eur J Cancer 2001, 37:1096–1103.
Delaney TF, Spiro IJ, Suit H, et al.: Neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2003, 56:1117–1127.
Grobmyer SR, Maki R, Demetri GD, et al.: Neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma: a matched case control study. Proc Am Soc Clin Oncol 2003.
Schlemmer M, Wendtner C, Lindner LH, et al.: Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term local failure- free survival for patients with high-risk soft tissue sarcomas. Proc Am Soc Clin Oncol 2003.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Phan, A., Patel, S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr. Treat. Options in Oncol. 4, 433–439 (2003). https://doi.org/10.1007/s11864-003-0044-5
Issue Date:
DOI: https://doi.org/10.1007/s11864-003-0044-5